Kathleen Mullane
Expertise in
6
conditions

Dr. Kathleen Mullane

Internal Medicine
University Of Chicago Medical Center
5841 S Maryland Ave, 
Chicago, IL 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
6
conditions
University Of Chicago Medical Center
5841 S Maryland Ave, 
Chicago, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Kathleen Mullane is an Internal Medicine provider in Chicago, Illinois. Dr. Mullane is highly rated in 6 conditions, according to our data. Her top areas of expertise are Shingles, Cytomegalovirus Infection, Cytomegalic Inclusion Disease, Nontuberculous Mycobacterial Lung Disease, and Bone Marrow Transplant.

Her clinical research consists of co-authoring 61 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Internal Medicine
Licenses
Internal Medicine in IL
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 1 Less Insurance Carrier -

Locations

University of Chicago Medical Center
5841 S Maryland Ave, Chicago, IL 60637

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase III Randomized Placebo-Controlled Study to Examine the Efficacy and Safety of DAS181 for the Treatment of Lower Respiratory Tract Parainfluenza Infection in Immunocompromised Subjects
A Phase III Randomized Placebo-Controlled Study to Examine the Efficacy and Safety of DAS181 for the Treatment of Lower Respiratory Tract Parainfluenza Infection in Immunocompromised Subjects
Enrollment Status: Recruiting
Publish Date: November 20, 2024
Intervention Type: Drug
Study Drug: DAS181
Study Phase: Phase 3
Open-Label Study to Evaluate the Efficacy and Safety of SCY-078 (Ibrexafungerp) in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment (FURI)
Open-Label Study to Evaluate the Efficacy and Safety of SCY-078 (Ibrexafungerp) in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment (FURI)
Enrollment Status: Completed
Publish Date: November 20, 2024
Intervention Type: Drug
Study Drug: Ibrexafungerp
Study Phase: Phase 3
Prevention of Respiratory Viruses Using Nozin in Stem Cell Transplant Recipients (PREV-NOSE Study)
Prevention of Respiratory Viruses Using Nozin in Stem Cell Transplant Recipients (PREV-NOSE Study)
Enrollment Status: Terminated
Publish Date: November 08, 2024
Intervention Type: Drug, Other
Study Phase: Phase 1
Phase IIb Study of F901318 as Treatment of Invasive Fungal Infections Due to Lomentospora Prolificans, Scedosporium Spp., Aspergillus Spp., and Other Resistant Fungi in Patients Lacking Suitable Alternative Treatment Options
Phase IIb Study of F901318 as Treatment of Invasive Fungal Infections Due to Lomentospora Prolificans, Scedosporium Spp., Aspergillus Spp., and Other Resistant Fungi in Patients Lacking Suitable Alternative Treatment Options
Enrollment Status: Completed
Publish Date: July 10, 2024
Intervention Type: Drug
Study Phase: Phase 2
A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients
A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients
Enrollment Status: Completed
Publish Date: March 03, 2023
Intervention Type: Drug, Other
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
Enrollment Status: Completed
Publish Date: November 03, 2021
Intervention Type: Drug
Study Phase: Phase 3
Study to Assess the Safety, Overall Tolerability, and Antiviral Activity of Brincidofovir Versus Standard of Care for Treatment of Adenovirus in High-risk Pediatric Allogeneic Hematopoietic Transplant Recipients
Study to Assess the Safety, Overall Tolerability, and Antiviral Activity of Brincidofovir Versus Standard of Care for Treatment of Adenovirus in High-risk Pediatric Allogeneic Hematopoietic Transplant Recipients
Enrollment Status: Terminated
Publish Date: January 25, 2021
Intervention Type: Other, Drug
Study Phase: Phase 2
A Prospective Observational Study for the Long-term Follow-up of Subjects Previously Enrolled in Selected Clinical Studies of CMX001.
A Prospective Observational Study for the Long-term Follow-up of Subjects Previously Enrolled in Selected Clinical Studies of CMX001.
Enrollment Status: Terminated
Publish Date: May 17, 2019
Intervention Type: Drug
View 7 Less Clinical Trials

61 Total Publications

Expect the unexpected: endocarditis caused by Legionella feeleii.
Expect the unexpected: endocarditis caused by Legionella feeleii.
Journal: Laboratory medicine
Published: May 23, 2024
Similar Doctors
Expertise in
9
conditions
Dr. Michel Gowhari
Internal Medicine
Expertise in
9
conditions
Dr. Michel Gowhari
Internal Medicine
1740 W Taylor St, 
Chicago, IL 
 (6.5 miles away)
866-600-2273
Languages Spoken:
English
See accepted insurances

Michel Gowhari is a primary care provider, practicing in Internal Medicine in Chicago, Illinois. Dr. Gowhari is highly rated in 9 conditions, according to our data. His top areas of expertise are Sickle Cell Disease, Hemoglobinopathy, Congenital Hemolytic Anemia, and Hemolytic Anemia.

Alfonso Tafur
Expertise in
41
conditions
Dr. Alfonso Tafur
Internal Medicine | Hospital Medicine | Dentistry
Expertise in
41
conditions
Dr. Alfonso Tafur
Internal Medicine | Hospital Medicine | Dentistry

Endeavor Health Medical Group

9650 Gross Point Rd., Suite 4900, 
Skokie, IL 
 (19.8 miles away)
847-663-8050
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Alfonso Tafur, MD, a cardiologist and director of vascular medicine services at Endeavor Health, specializes in managing blood clot disorders and vascular disease. He provides personalized, continuing care while leading research to improve treatment options for complex conditions. Dr. Tafur listens closely to understand each patient’s experience and works to guide them through every phase of their healthcare journey with compassion and precision. Dr. Tafur is highly rated in 41 conditions, according to our data. His top areas of expertise are Venous Thromboembolism (VTE), Deep Vein Thrombosis, Pulmonary Embolism, Hepato-Pancreato-Biliary Surgery, and Knee Replacement.

Expertise in
7
conditions
Dr. Rekha Vij
Internal Medicine
Expertise in
7
conditions
Dr. Rekha Vij
Internal Medicine
5841 S Maryland Ave, Mc 7082, 
Chicago, IL 
 (0.1 miles away)
773-702-9296
Languages Spoken:
English
See accepted insurances

Rekha Vij is a primary care provider, practicing in Internal Medicine in Chicago, Illinois. Dr. Vij is highly rated in 7 conditions, according to our data. Her top areas of expertise are Acute Interstitial Pneumonia, Pulmonary Fibrosis, Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis, and Lung Transplant.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mullane's expertise for a condition
ConditionClose
    View All 22 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile